Key result
Concomitant PPI use modestly increased platelet reactivity in extensive CYP2C19 metabolizers with ACS on clopidogrel, but caused no significant change in poor metabolizers.
Why the study?
The interaction between proton pump inhibitors and clopidogrel in ACS patients is mediated by CYP2C19 genetic variants, warranting quantitative assessment of genotype-dependent pharmacokinetic and pharmacodynamic impacts.
Does concomitant pantoprazole or lansoprazole use affect clopidogrel pharmacodynamics and pharmacokinetics in a CYP2C19 genotype-dependent manner in Chinese ACS patients?
Observational (n=409)
Does concomitant pantoprazole or lansoprazole use affect clopidogrel pharmacodynamics and pharmacokinetics in a CYP2C19 genotype-dependent manner in Chinese ACS patients?
Answers are grounded in this paper and cite their sources.
Concomitant PPI use modestly increases platelet reactivity in extensive CYP2C19 metabolizers on clopidogrel, but not in poor metabolizers, an interaction that can be accurately predicted using integrated PBPK/PD modeling.
Purpose The interaction between proton pump inhibitors (PPIs) and clopidogrel in acute coronary syndrome (ACS) patients is mediated by CYP2C19 genetic variants. This study quantitatively assessed their CYP2C19 genotype-dependent impact on clopidogrel pharmacokinetics and pharmacodynamics using clinical data and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling. Methods A total of 409 ACS patients from a prospective clinical study were genotyped for CYP2C19 (*1, 2, and 3 alleles) and evaluated for platelet reactivity index (PRI) following clopidogrel therapy, with or without concomitant pantoprazole or lansoprazole use. A PBPK model was developed in PK-Sim, incorporating CYP2C19-specific metabolic pathways, and linked with a pharmacodynamic model of P2Y12 receptor inhibition to simulate the effects of genotypes and PPIs on platelet inhibition. Results In extensive metabolizer individuals, PPI coadministration modestly increased platelet reactivity, while no significant change occurred in poor metabolizers. The PBPK simulations accurately predicted pharmacokinetic parameters, with over 90% of Cmax and AUC values within 0.5–twofold of clinical data. The integrated drug-drug-gene interaction–pharmacodynamic framework effectively captured the active metabolite’s exposure and platelet inhibition dynamics. Conclusions These results provide a quantitative understanding of the genotype- and PPI-dependent effects on clopidogrel’s pharmacodynamics, offering a tool to personalize therapy in ACS patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted an observational in Acute coronary syndrome (ACS) (n=409). Concomitant proton pump inhibitors (pantoprazole or lansoprazole) vs. Clopidogrel therapy without concomitant PPI use was evaluated on Platelet reactivity index (PRI). Concomitant PPI use modestly increased platelet reactivity in extensive CYP2C19 metabolizers with ACS on clopidogrel, but caused no significant change in poor metabolizers.
Synapse has enriched 10 related papers. Consider them for comparative context: